Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836925 | 0.78 | AOC3 (0.46) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL1082423 | 0.78 | CYP2D6 (0.43) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL9263647 | 0.77 | CA1 (0.47) | CYP2D6MAPK1CES2CES1 | |
| SCHEMBL288096 | 0.77 | CYP2D6 (0.41) | KCNA5CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL7826397 | 0.77 | ALDH1A1 (0.45) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL17841494 | 0.77 | CYP2D6 (0.41) | KCNA5CYP2D6SRCDPP4F2 | |
| SCHEMBL8572896 | 0.77 | CYP2C19 (0.43) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL28827939 | 0.77 | DPP4 (0.50) | KCNA5DPP4F2LMNA | |
| SCHEMBL27583003 | 0.76 | CYP2D6 (0.42) | KCNA5CYP2D6SRCDPP4F2 | |
| SCHEMBL6285588 | 0.75 | KCNA5 (0.45) | KCNA5CYP2D6SRCDPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562927-B1 | THIO-ANALOGUES OF PACLITAXEL AND INTERMEDIATES THEREOF | CHATHAM BIOTEC LTD (CA) | 2009-05-13 | — | — | EP | disclosed |
| US-20070032646-A1 | Novel taxanes and methods related to use and preparation thereof | INNOVATIONAL HOLDINGS LLC | 2007-02-08 | — | — | US | disclosed |
| CN-1703409-A | Novel taxanes and methods related to use and preparation thereof | PHYTOGEN LIFE SCIENCES INC (CA) | 2005-11-30 | — | — | CN | disclosed |
| EP-1562927-A2 | THIO-ANALOGUES OF PACLITAXEL AND INTERMEDIATES THEREOF | Phytogen Life Sciences Inc. (CA) | 2005-08-17 | — | — | EP | disclosed |
| US-20040132991-A1 | Novel taxanes and methods related to use and preparation thereof | PHYTOGEN LIFE SCIENCES INC. (CA) | 2004-07-08 | — | — | US | disclosed |
| WO-2004033442-A2 | NOVEL TAXANES AND METHODS RELATED TO USE AND PREPARATION THEREOF | CHATHAM BIOTEC LTD. (CA) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032646-A1 | Novel taxanes and methods related to use and preparation thereof | TUBB8B, TUBA1B, TUBB | KCNA5 4764/4885CYP2D6 979/4885SRC 3160/4885 |
| US-20040132991-A1 | Novel taxanes and methods related to use and preparation thereof | TUBB8B, TUBA1B, TUBB | KCNA5 4764/4885CYP2D6 979/4885SRC 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.